In a filing, MoonLake Immunotherapeutics revealed its Former 10% Owner Chen Bihua unloaded Company’s shares for reported $46.83 million on Sep 29 ’25. In the deal valued at $7.21 per share,6,494,151 shares were sold. As a result of this transaction, Chen Bihua now holds 2,000,000 shares worth roughly $17.32 million.
Then, Chen Bihua sold 5,827 shares, generating $40,556 in total proceeds. Upon selling the shares at $6.96, the Former 10% Owner now owns 1,994,173 shares.
Before that, Moukheibir Catherine sold 23,500 shares. MoonLake Immunotherapeutics shares valued at $1,146,565 were divested by the Director at a price of $48.79 per share. As a result of the transaction, Moukheibir Catherine now holds 0 shares, worth roughly $0.0.
H.C. Wainwright downgraded its MoonLake Immunotherapeutics [MLTX] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early October from “a Buy” to “a Neutral”. Wolfe Research also remained covering MLTX and has decreased its forecast on September 30, 2025 with a “an Underperform” recommendation from previously “an Outperform” rating. Citigroup revised its rating on September 30, 2025. It rated MLTX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of MLTX
On Monday, MoonLake Immunotherapeutics [NASDAQ:MLTX] saw its stock jump 2.73% to $8.66. Over the last five days, the stock has gained 38.67%. MoonLake Immunotherapeutics shares have fallen nearly -83.29% since the year began. Nevertheless, the stocks have fallen -84.01% over the past one year. While a 52-week high of $62.75 was reached on 09/26/25, a 52-week low of $5.95 was recorded on 09/29/25.
Levels Of Support And Resistance For MLTX Stock
The 24-hour chart illustrates a support level at 8.29, which if violated will result in even more drops to 7.91. On the upside, there is a resistance level at 9.28. A further resistance level may holdings at 9.89.
How much short interest is there in MoonLake Immunotherapeutics?
A steep rise in short interest was recorded in MoonLake Immunotherapeutics stocks on 2025-09-15, dropping by -0.42 million shares to a total of 4.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 5.37 million shares. There was a decline of -8.43%, which implies that there is a negative sentiment for the stock.
